Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $64,685.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $7.61, for a total transaction of $64,685.00. Following the completion of the sale, the chairman owned 3,444,322 shares of the company’s stock, valued at approximately $26,211,290.42. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.23, for a total value of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total transaction of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Stock Down 0.5%

SOPH opened at $7.57 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a fifty-two week low of $2.99 and a fifty-two week high of $7.88. The company has a fifty day moving average of $5.79 and a two-hundred day moving average of $5.19. The stock has a market capitalization of $635.05 million, a price-to-earnings ratio of -6.58 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, research analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SOPH. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. HC Wainwright raised their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.00.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently bought and sold shares of the business. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the fourth quarter worth approximately $49,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter worth $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth about $50,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter valued at $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.